
Morr F5%
Technokit Healthcare Ltd
FINASTERIDE + MINOXIDIL is a combination regimen used in the treatment of male pattern hair loss (androgenetic alopecia) and more.
FINASTERIDE + MINOXIDIL is a combination regimen used in the treatment of male pattern hair loss (androgenetic alopecia), combining an oral or topical 5-alpha-reductase inhibitor (finasteride) with a topical hair-growth stimulant/vasodilator (minoxidil).
FINASTERIDE + MINOXIDIL is not indicated for the prevention of hair loss unrelated to androgenetic alopecia, and does not treat scarring alopecia.
| Component | Typical adult dose | Route/Frequency |
|---|---|---|
| Finasteride | 1 mg (oral tablet), or as a compounded topical solution where prescribed | Oral: once daily, with or without food. Topical: as directed, usually once daily. |
| Minoxidil | 1 mL of 2% or 5% solution, or a cap-full of foam | Applied topically to the affected areas of the dry scalp, usually twice daily (morning and evening) |
FINASTERIDE + MINOXIDIL is not approved for use in women or in children; it is intended for adult men with androgenetic alopecia. Consistent daily use is required, and visible benefit typically takes several months to appear (see Duration of Treatment).
No specific dose adjustment of FINASTERIDE + MINOXIDIL is well established for renal impairment. Finasteride has not been specifically studied in hepatic impairment; use with caution, as finasteride is metabolized by the liver.
Report any persistent or bothersome side effect from FINASTERIDE + MINOXIDIL to the prescribing physician.
FINASTERIDE + MINOXIDIL is not intended for use in children.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.